PREVALENCE OF ASSOCIATED SYMPTOMS

In a post hoc analysis of 2 ACIPHEX® clinical studies in nonerosive GERD patients with moderately severe heartburn symptoms…

A majority of patients experienced baseline regurgitation and belching in addition to heartburn1

Post hoc analysis of pooled data from 2 randomized, double-blind, placebo-controlled studies in adult nonerosive GERD patients with moderate to very severe heartburn symptom episodes (N=252) occurring 5 or more times during the last week of a 2-week placebo run-in period.1

69% of patients also experienced Regurgitation Orange Divider 88% of patients also experienced Belching

*≥3 symptom episodes during the last week of a 2-week placebo run-in period.

 
INDICATIONS
  • In adults (≥18 years of age), ACIPHEX® 20 mg is indicated for: treatment of daytime and nighttime heartburn and other symptoms associated with GERD; short-term, up to 4 weeks, treatment in the healing and symptomatic relief of duodenal ulcers; short-term, 4 to 8 weeks, treatment in the healing and symptomatic relief of erosive GERD; and maintenance of healing and reduction in relapse rates of heartburn symptoms in erosive GERD (controlled maintenance studies do not extend beyond 12 months)
IMPORTANT SAFETY INFORMATION
Contraindications:
  • ACIPHEX® is contraindicated in patients with known hypersensitivity to rabeprazole, substituted benzimidazoles, or to any component of the formulation
Warnings and Precautions:
  • Symptomatic response to therapy does not preclude the presence of gastric malignancy
  • As with all PPIs, patients treated concomitantly with warfarin may need to be monitored for increases in INR and prothrombin time. Increases in INR and prothrombin time may lead to abnormal bleeding and even death
  • Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine
  • Hypomagnesemia has been reported rarely with prolonged treatment with PPIs. Serious adverse events include tetany, arrhythmias, and seizures. Consider monitoring magnesium levels in patients on prolonged PPI therapy or concomitant medications such as digoxin or medications that may cause hypomagnesemia (eg, diuretics)
Adverse Events:
  • In adults, clinical trials revealed the following adverse reactions appearing in ≥2% of ACIPHEX® patients and with a frequency greater than placebo: pain, pharyngitis, flatulence, infection, and constipation
Drug Interactions:
  • ACIPHEX® inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin)
  • ACIPHEX® may reduce the plasma levels of atazanavir
  • Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro

For more information about ACIPHEX®, see full Prescribing Information.

Click here to view full Prescribing Information for ACIPHEX®.

Reference: 1. Kahrilas P, DeLemos B, Xiang J, LoCoco J, Kassalow L, Li H. Associated symptoms in nonerosive gastroesophageal reflux disease (NERD): effect of PPI therapy [OESO abstract 67]. J Clin Gastroenterol. 2008;42(suppl 1):S11.

 
Thank you for visiting aciphex360.com.
By clicking "Continue" you will be taken to: